Type 2 diabetes mellitus - Its global prevalence and therapeutic strategies

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 4, Issue 1, 2010, Pages 48-56

  Jain, Shelesh ^a   Saraf, Swarnlata ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

GLP 1; IKKB; PPAR; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CARBAMAZEPINE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DISULFIRAM; ERYTHROMYCIN; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; KETOCONAZOLE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; SULFONYLUREA; TIPRANAVIR; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGE; ANEMIA; ANOREXIA; APLASTIC ANEMIA; ARTHROPATHY; BACKACHE; CELL TRANSPLANTATION; CHOLESTATIC HEPATITIS; CONSTIPATION; COUGHING; DEMOGRAPHY; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG ABSORPTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG RELEASE; DRUG SAFETY; DYSPEPSIA; ETHNICITY; FATIGUE; FLATULENCE; FLUID RETENTION; GENE EXPRESSION PROFILING; HEADACHE; HEART FAILURE; HEARTBURN; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN PUMP; INSULIN RELEASE; JAUNDICE; LACTIC ACIDOSIS; LEUKOPENIA; LIFESTYLE MODIFICATION; MENSTRUATION DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 79551592855     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.04.011     Document Type: Review

References (92)

1. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-83.
2. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-40. (Pubitemid 33716504)
3. Lenhard JM, Gottschalk WK. Preclinical developments in type II diabetes. Adv Drug Deliv Rev 2002;54:1199-212.
4. Chen KW, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995;18:747-53.
5. Haffner SM, Miettinin H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of type 2 DM in Mexican-Americans. Diabetes 1995;44:1386-91.
6. Diabetes Atlas. International Diabetes Federation, Press Release, Cape Town, South Africa, 4 December; 2006.
7. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults, the third National health and Nutrition examination survey, 1988-1994. Diabetes Care 1998;21:518-24. (Pubitemid 28172927)
8. King H, Rewers M. Global estimates for prevalence of diabetes and impaired glucose tolerance in adults. Diabetes Care 1993;16:157-77. (Pubitemid 23013841)
9. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;8:1929-38. (Pubitemid 350192633)
10. Nwobu CO, Johnson CC. Targeting obesity to reduce the risk for type 2 diabetes and other co-morbidities in African American youth: a review of the literature and recommendations for prevention. Diab Vasc Dis Res 2007;4:311-9.
11. Simmons D, Williams DR, Powell MY. Prevalence of diabetes in a predominately Asian community; findings of the Coventry diabetes study. Brit Med J 1989;298:18-21. (Pubitemid 19022881)
12. Bril A, Ktorza A. A better understanding of the pathophysiology of obesity and type 2 diabetes: a clue for new therapeutic approaches. Curr Opin Pharmacol 2006;6:577-9. (Pubitemid 44660953)
13. Mshelia DS, Akinosun OM, Abbiyesuku FM. Effect of increased patient-physician contact time and health education in achieving diabetes mellitus management objectives in a resource-poor environment. Singapore Med J 2007;48:74-9. (Pubitemid 351229126)
14. Roger G. Epidemiology of diabetes. Adv Drug Deliv Rev 2002;54:1165-72.
15. Goldfine AB. Type 2 diabetes: new drugs, new perspectives. Hosp Pract 2001;36:29-36.
16. Stefano DP, Pulizzi N. The place of sulfonylureas in the therapy for T2DM mellitus. Metabolism 2006;55(Suppl. 1):S20-7.
17. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of T2DM (UKPDS 36): prospective observational study. Brit Med J 2000;321:412-9. (Pubitemid 30609443)
18. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 antidiabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 2007;73:84-93. (Pubitemid 44853930)
19. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: whatisthe evidence? Diab Vasc Dis Res 2005;2:61-6. (Pubitemid 40826997)
20. Lo D, Hilbush B, Mah S, Brayden D, Byrne D, Higgins L, et al. Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling. Adv Drug Deliv Rev 2002;54:1213-23. (Pubitemid 35223418)
21. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119(5 Suppl. 1):10S-6S.
22. Sershen S, West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2002;54:1225-35. (Pubitemid 35223419)
23. Ulbrich K, Subr V, Podperova P, Buresova M. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release. J Control Release 1995;34: 155-65.
24. Jiang HL, Zhu KJ. Pulsatile protein release from a laminated device comprising of polyanhydrides and pH-sensitive complexes. Int J Pharm 2000;194:51-60.
25. Tildesley HD, Aydin CM, Ignaszewski A, Strelzow JA, Yu E, Bondy G. Sulfonylurea therapyis associated with increased NT-proBNP levelsinthe treatment of type 2 diabetes. Int J Cardiol 2007;115:312-7. (Pubitemid 46185631)
26. Neuvonen PJ, Karkkainen S, Lehtovaara R. Pharmacokinetics of chlorprop-amide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. Eur J Clin Pharmacol 1987;32:297-301. (Pubitemid 17069120)
27. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes. Diabetes 2004;53(Suppl. 3):S151-5. (Pubitemid 39564537)
28. Lebovitz H, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGM, Zimmet P, DeFronzo RA, editors. International textbook of diabetes mellitus. 2nd ed., London: Wiley; 1997. p. 817-40.
29. Moses AM, Numann P, Miller M. Mechanism of chlorpropamide-induced antiduretics in man: evidence for release of ADH and enhancement of peripheral action. Metabolism 1973;22:59-66.
30. Rendell M. The role of sulphonylureas in the management of T2DM. Drugs 2004;64:1339-58.
31. Lindblad U, Lindwall K, Sjöstrand A, Ranstam J, Melander A. The NEPI antidiabetes study (NANSY) 1 short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes Obes Metab 2001;3:443-51. (Pubitemid 34030864)
32. Bitzen PO, Melander A, Schersten B, Wahlin-Boll E. Influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycemia. Eur J Clin Pharmacol 1988;35:31-7.
33. Jonsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994;17:142-5. (Pubitemid 24035310)
34. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diab Res Clin Pract 2007;77:58-61. (Pubitemid 46590477)
35. Hansen AM, Christensen IT, Hansen IB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the sulphonylurea receptor 1. Diabetes 2002;51:2789-95. (Pubitemid 34970932)
36. Norman P, Rabasseda X. Nateglinide - a structurally novel, short-acting, hypoglycemic aqgent. Drugs Today 2001;37:411-26.
37. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002;41:471-83. (Pubitemid 34804160)
38. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGM, Zimmet P, DeFronzo RA, editors. International textbook of diabetes mellitus. 2nd ed., London: Wiley; 1997. p. 841-64.
39. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996;36:1012-21. (Pubitemid 27014728)
40. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 2001;121:19-25. (Pubitemid 32916692)
41. Chapelsky MC, Thompson CK, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003;43:252-9. (Pubitemid 36232653)
42. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108.
43. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120.
44. Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H. Pharmacokinetics of acarbose Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs. Arzneimittelforschung 1989;39:1261-7. (Pubitemid 19255302)
45. Brownsey RW, Denton RM. In: Boyer PD, Krebs EG, editors. Acetyl-coenzyme A carboxylase, vol. 18. Miami: Academic Press; 1987. p. 123-46.
46. Thampy KG. Formation of malonyl coenzyme A in rat heart Identification and purification of an isozyme of A carboxylase from rat heart. J Biol Chem 1989;264:17631-4.
47. Bianchi A, Evans JL, Iverson AJ, Nordlund AC, Watts TD, Witters LA. Identification of an isozymic form of acetyl CoA carboxylase. J Biol Chem 1990;265: 1502-9.
48. Abu LE, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G, Wakil SJ. The subcellular localization of acetyl CoA carboxylase 2. Proc Natl Acad Sci 2000;97:1444-9. (Pubitemid 30118460)
49. Pickup JC, Crook MA. Istype II diabetes mellitusadisease of the innate immune system? Diabetologia 1998;41:1241-8. (Pubitemid 28449093)
50. Festa A, Agostino RD, Howard G. Chronic subacute inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study. Circulation 2000;102:42-7. (Pubitemid 30430551)
51. Feldmann M, Maini RN. Anti-TNFa therapy ofrheumatoid arthritis: what have we learned. Annu Rev Immunol 2001;19:163-96. (Pubitemid 32368033)
52. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993;259:87-91. (Pubitemid 23036092)
53. Hurel S, Ofei F, Wells AN, Newkirk J. TNFa and insulin sensitivity in humans: effectsin vivo of antibody blockadein obese NIDDM patients and invitro upon human cultured myotubes. Exp Clin Endrocrinol Diabetes 1996;104(Suppl. 2):59-60.
54. Goetze S, Kintscher U, Kawano H, Kawano Y, Wakino S, Fleck E, et al. Tumor necrosis factor alpha inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2000;275:18279-83. (Pubitemid 30414781)
55. Zhang B, Berger J, Hu E, Szalkowski D, White-Carrington S, Spiegelman BM, et al. Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor alfa. Mol Endocrinol 1996;10:1457-66. (Pubitemid 26423234)
56. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
57. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46. (Pubitemid 32730790)
58. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343: 230-8. (Pubitemid 30490390)
59. Arulmozhi DK, Portha B. GLP-1 based therapy for T2DM. Eur J Pharm Sci 2006;28:96-108.
60. Combettes MM. GLP-1 and type 2 diabetes - physiology and new clinical advances. Curr Opin Pharmacol 2006;6:598-605. (Pubitemid 44660946)
61. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin dependant) diabetes. Diabetologia 1986;29:46-52. (Pubitemid 16162741)
62. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced post-prandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-11.
63. Gautier JF, Fetita S, Sobngwi E, Martin Cs. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005;31:233-42. (Pubitemid 40961520)
64. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagons-like peptide 1(7-36) amide in type 2 (non-insulin dependent) diabetic patients. Diabetologia 1993;36: 741-4. (Pubitemid 23218642)
65. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998;21: 1925-31. (Pubitemid 28478295)
66. Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53. (Pubitemid 26397366)
67. Ahren B. Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type-2 diabetes. Drug Discov Today 2004;1:207-12. (Pubitemid 40197629)
68. Ahren B, Schimitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76. (Pubitemid 40115912)
69. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry-A novel kinetic approach. J Biol Chem 1996;271:23222-9. (Pubitemid 26314761)
70. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001;284:501-6. (Pubitemid 32918006)
71. McIntosh CH. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front Biosci 2008;13:1753-73.
72. McIntyre HF, Grant P. Dipeptidyl peptidase-IV inhibitors: fixing type 2 diabetes? Br J Hosp Med (Lond) 2007;68:599-602. (Pubitemid 350195872)
73. Attali JR. CS-II in type 2 diabetic patients. Diabetes Res Clin Pract 2006;74: S116-8.
74. James FT, Leonard PF. Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. Trends Endocrinol Metab 2006;17:284-90.
75. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator activated receptors (PPAR). Toxicol Sci 2006;90:269-95.
76. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
77. Lowell BB. PPAR-gamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999;99:239-42. (Pubitemid 29519902)
78. Cascieri MA, Fong TM, Strader CD. Molecular characterization of a common binding site for small molecules within the transmembrane domain of Gprotein coupled receptors. J Pharmacol Toxicol Methods 1995;33:179-85.
79. Madsen P, Brand CL, Holst JJ, Knudsen B. Advances in non-peptide glucagon receptor antagonists. Curr Pharm Des 1999;5:683-91. (Pubitemid 29510791)
80. Madsen P, Knudsen LB, Wiberg FC, Carr RD. Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 1998;41:5150-7. (Pubitemid 29016309)
81. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem 1999;274:8694-7. (Pubitemid 29164665)
82. de Laszlo SE, Hacker C, Li B, Kim D, MacCoss M, Mantlo N, et al. Potent, orally absorbed glucagon receptor antagonists. Bioorg Med Chem Lett 1999;9: 641-6. (Pubitemid 29130262)
83. Petersen K, Sullivan J, Amatruda J. The effects of a specific glucagon antagonist on glucagon stimulated glucose production. In: Abstract 150 of the 35th Annual Meeting of the European Association for Study of Diabetes; 1999.
84. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001;44:2018-24. (Pubitemid 33124047)
85. Reifsnyder PC, Leiter EH. Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes 2002;51:825-32. (Pubitemid 34760196)
86. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, et al. Tissuespecific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000;105:199-205. (Pubitemid 30054359)
87. Luna B, Feinglos MN. Oral agents in the management of T2DM. Am Fam Phys 2001;63:1747-56.
88. Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, et al. Treatment of T2DM with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004;63:127-34. (Pubitemid 38096358)
89. Koh KK, Quon MJ, Han SH, Ahn JY, Lee Y, Shin EK. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 + 2 in patients with type 2 diabetes. Atherosclerosis 2007;194:230-7. (Pubitemid 47464302)
90. Mafauzy M. Repaglinide versus glibenclamide treatment of T2DM during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45-53. (Pubitemid 34823624)
91. Garg R, Gopal J, Jones GR. Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled T2DM patients treated with insulin alone. J Diabetes Complications 2007;21:1-6. (Pubitemid 44960840)
92. Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-88. (Pubitemid 44067262)